Leukemia and Lymphoma

FDA Updates Imbruvica Label With 5-Year Data in Waldenström Macroglobulinemia

December 23rd 2020, 3:44pm


The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.

NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL, SLL

December 23rd 2020, 1:00pm


The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma, as a first-line and second-line therapy for treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The 6 Factors That Predict ICU Admission in Patients With Hematologic Cancers

December 17th 2020, 12:00pm


Both clinical and physician-based factors play a role in the risk of a patient with hematologic malignancies ending up in the ICU.

Venetoclax With Decitabine Outperforms Intensive Chemotherapy in Older Patients With AML

December 15th 2020, 11:00pm


A new study may help clear up questions about the superiority of venetoclax with hypomethylating agents in patients who are deemed to be at high risk of treatment-related mortality.

Immunological Status Affects Efficacy of Mogamulizumab in ATL, Study Finds

December 10th 2020, 1:00pm


A new study helps explain immunological factors that appear to have an impact on the success rate of mogamulizumab in patients with adult T-cell leukemia-lymphoma (ATL).

Dr Ian Flinn: Venetoclax, BTK Inhibitor Combination May Induce Greater Remission in Patients With CLL

December 8th 2020, 7:00pm


SEQUOIA arm D study results show better outcomes are possible for patients with 17p-deletion CLL, explained Ian Flynn, MD, PhD, director of lymphoma research at Sarah Cannon Research Institute.

Single-Agent Ibrutinib Leads to Durable Responses in Relapsed/Refractory MZL

December 2nd 2020, 9:15pm


Patients who previously were treated with rituximab saw durable responses when given single-agent ibrutinib, and the drug’s safety profile in a new study matches earlier findings.

Dr Michael Green: Neurotoxicity, Poor Molecular Response Are Top Investigative Priorities

November 26th 2020, 2:00pm


Investigating circulating tumor DNA is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.

Late Effects of Therapy Plague Many Patients Who Survived AML as Youths, Young Adults

November 23rd 2020, 12:30pm


Most patients who are diagnosed with acute myeloid leukemia are in middle or old age. The relatively small number who are diagnosed earlier in life can be subject to long-term health risks due to their treatment.

Rituximab Lowers Health Care Costs in DLBCL, Japanese Study Finds

November 21st 2020, 3:15pm


A new report finds including rituximab in first-line therapy for diffuse large B-cell lymphoma (DLBCL) results in better overall outcomes that more than offset the higher initial cost of therapy.